Serotonin (5-HT) induces shape change and aggregation of platelets, vasoconstriction and increase of vascular permeability and cell proliferation, [1] [2] [3] [4] [5] after release from the site of vascular injury. The 5-HT 2 A receptor is thought to be involved in all of these 5-HT mediated pathophysiological effects. [6] [7] [8] Kihara et al. 9) reported that AT-1015 (N-[2-[4-(5H-dibenzo-[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), a newly synthesized 5-HT 2 antagonist, blocked vascular and platelet 5-HT 2 A receptors and prevented laurate-induced peripheral vascular lesion in rats. The inhibitory activity and selectivity of AT-1015 towards 5-HT 2 A receptor-mediated platelet aggregation was almost equivalent to ketanserin. Previously, we reported that AT-1015 was a strong noncompetitive 5-HT 2 antagonist compared to ketanserin and that it inhibited the contraction response of porcine coronary arteries induced by 5-HT and a-methylserotonin. 10) In this study, we demonstrated the binding affinity of AT-1015 to 5-HT 2 receptor in rabbit platelet membranes using [
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MATERIALS AND METHODS

Materials [
3 H]Ketanserin (63.3 Ci/mmol) was purchased from NEN Life Science Products, Inc. (Boston, MA, U.S.A.). AT-1015 used in the study was donated by Ajinomoto Co., Ltd., Tokyo, Japan. Ketanserin and ritanserin were obtained from RBI (Research Biochemicals Incorporated, Natick, MA, U.S.A.) and cyproheptadine was obtained from SIGMA (Sigma Chemical Co., St. Louis, MO, U.S.A.). Sarpogrelate was obtained from Mitsubishi Chemical Corporation, Tokyo, Japan. The chemical structure of AT-1015 is shown in Fig. 1 .
Preparation of Membrane-Enriched Fraction Male rabbits (Japanese, white, 3-4 kg) were anesthetized by i.v. injection of sodium pentobarbital (25 mg/kg). A polyethylene extension tube was introduced in the carotid artery via an incision in the neck. The first 2-3 ml blood was discarded, and the blood was at first collected by a 50 ml plastic syringe containing 0.38% trisodium citrate and then it was gently decanted to a 50 ml plastic centrifuge tube. Membrane preparation of platelet was performed according to the method of Tsuchihashi et al. 11) with slight modification. Platelet-rich plasma (PRP) was obtained by centrifugation of the blood at 180ϫg for 15 min at 10°C. Residual erythrocytes and leukocytes were removed by another centrifugation at 200ϫg for 15 min at 10°C. The PRP was then centrifuged at 30000ϫg for 10 min at 4°C and the resultant platelet-rich pellet was suspended in hypotonic Tris-EDTA (5 mM Tris-HCl, 0.1% EDTA, pH 7.5) using Polytron homogenization at a setting of 7 for 10 s. The suspension was centrifuged at 40000ϫg for 15 min at 4°C and the membranes were re-suspended in the same buffer using Polytron homogenization as described above. After the same centrifugation procedure, the pellet was finally re-suspended in the assay buffer, which consisted of 60 mM Tris-HCl, 20 mM MgCl 2 , pH 7.4. The platelet membrane-enriched fraction was then immediately frozen in liquid nitrogen and stored at Ϫ80°C until used. Membrane protein concentrations were determined by the method of Bradford 12) with bovine serum albumin used as standard. Binding Assay The radioligand binding assays for the determination of affinity for 5-HT 2 receptor subtype were performed according to the method described previously. 13) Experiments were performed at a final volume of 500 ml of assay buffer (60 mM Tris-HCl, 20 mM MgCl 2 , pH 7.4) with 50 ml of [ 3 H]-ketanserin, 100 ml of membrane preparation (0.1 mg of protein) and 50 ml of vehicle or test solution containing various concentrations of the test compounds. The concentration of [ 3 H]-ketanserin ranged from 0.12 nM to 10.0 nM for the saturation binding experiments, and a concentration of 1.0 nM was used for the competition binding experiments. After 30 min incubation at 23°C, the reaction mixture was rapidly filtered under vacuum through a Whatman GF/C glass fiber filter and was followed by five 2.0 ml washes with ice-cold 50 mM Tris-HCl buffer (pH 7.4). The filter mats were pre-soaked in 0.1% polyethyleneimine (PEI) to reduce filter binding. The retained radioactivity in the vial which contained the filter with 2 ml of toluene-trinitron based scintillation fluid was determined using a liquid scintillation counter (Packard 2200 Tri-Carb Scintillation Analyser). The specific binding was determined by subtracting the remaining nonspecific binding in the presence of 0.1 mM 5-HT from the total binding.
Kinetic Analysis Data are given as the meansϮS.E. The dissociation constants (K d ) and the density of 5-HT 2 receptor binding sites (B max ) in the membrane preparation of the rabbit platelet membrane were determined by linear regression analysis of the saturation binding curves transformed to Scatchard plots. IC 50 (inhibitory concentration 50%) and K i (inhibition constant) were analyzed using Prism, a nonlinear curve-fitting program (Graph Pad Software, Inc. CA, U.S.A.). Most of the K i values are expressed as pK i (-log K i ) in this report. Significance of the data was evaluated using Student's t-test.
RESULTS
The specific binding of [ 3 H]-ketanserin to rabbit platelet membranes occurred at a saturable single site in the range from 0.12 to 10.0 nM. Specific binding represented 40-60% of the total radioactivity bound to the platelet membranes. The B max value and K d value were 806.72Ϯ82.41 fmol/mg protein and 4.64Ϯ1.18 nM, respectively ( Table 1) .
The pK i values of AT-1015 and other 5-HT 2 antagonists to 5-HT 2 receptors in rabbit platelet are shown in the Table 2 . The pK i value of ketanserin was higher than those of other 5-HT 2 antagonists. The pK i value of the newly synthesized 5-HT 2 antagonist, AT-1015 also showed a high value (7.40). The pK i values of ritanserin, sarpogrelate and cyproheptadine were 7.25, 7.20 and 6.20 respectively.
DISCUSSION
Our investigation showed that the specific binding of [ 3 H]-ketanserin to rabbit platelet membranes was saturable in the range from 0.12 to 10.0 nM and the specific binding was 40-60% of the total radioactivity bound to the platelet membrane. These results were similar to those reported by Tsuchihashi et al. 11) in rabbit platelet and Leysen et al. 14) in cat platelet. These authors reported that only 40% binding of the total [ 3 H]-ketanserin binding represented true 5-HT 2 receptor binding and the other 60% of the binding was at another binding site when the displacement experiments were carried out using 5-HT 2 antagonists, and nonspecific binding was determined in the presence of ketanserin. They also reported that this 60% of [ 3 H]-ketanserin binding was inhibited by high concentrations of ketanserin between 10 and 100 nM. The concentration of serotonin (5-HT) for determination of non-specific binding was therefore set at 0.1 mM and the specific binding was determined by subtracting the non-specific binding from the total binding.
The present study examined the displacement potencies of 5-HT 2 antagonists for [
3 H]-ketanserin binding to 5-HT 2 receptor in rabbit platelet membrane. Ketanserin had the highest affinity for the 5-HT 2 receptor site in the rabbit platelet membrane among the 5-HT 2 antagonists used in the present study. AT-1015, a newly synthesized 5-HT 2 antagonist, also had high affinity for this binding site although its affinity was slightly lower than ketanserin. Sarpogrelate and ritanserin also had high affinity, but lower than ketanserin. In contrast, the displacement potency of cyproheptadine was lower for this binding site. Previously, Tsuchihashi et al. 11) and Maruyama et al. 15) also reported that sarpogrelate had high affinity for the 5-HT 2 receptor site in both rabbit platelet and rat frontal lobe, while the value for cyproheptadine was significantly lower than those in the rat frontal lobe.
Kihara et al. 9) reported that AT-1015, a novel 5-HT 2 receptor antagonist, selectively inhibited in vitro 5-HT 2 A receptormediated platelet aggregation and effectively prevented progression of peripheral vascular lesions in rats. Our previous paper 10) showed that AT-1015 was a strong noncompetitive 5-HT 2 antagonist compared with ketanserin and inhibited the contraction response of porcine coronary arteries mediated by 5-HT and a-methylserotonin. The present study also confirmed the high affinity of AT-1015 in the platelet membrane. Thus, we predict that the high affinity of AT-1015 in rabbit platelet may play an important role in its biological effects i.e. its inhibitory effect on platelet aggregation 9) and inhibition of contraction response in porcine coronary artery 10) and this agent may be expected to be useful for the therapeutic treatment of peripheral, cerebral or coronary ischemia caused by the aggregation of platelets mediated by 5-HT 2 receptor activation. 
